Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8085) 8085
Book Review (1191) 1191
Publication (959) 959
Newsletter (747) 747
Newspaper Article (142) 142
Conference Proceeding (72) 72
Book Chapter (47) 47
Magazine Article (44) 44
Trade Publication Article (9) 9
Web Resource (3) 3
Data Set (2) 2
Transcript (2) 2
Book / eBook (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
tenofovir (6739) 6739
index medicus (5274) 5274
humans (5147) 5147
female (2819) 2819
male (2660) 2660
infectious diseases (2638) 2638
adenine - analogs & derivatives (2613) 2613
hiv (2509) 2509
hiv infections - drug therapy (2489) 2489
adult (2284) 2284
middle aged (1720) 1720
human immunodeficiency virus--hiv (1555) 1555
anti-hiv agents - therapeutic use (1521) 1521
immunology (1491) 1491
emtricitabine (1483) 1483
hepatitis b (1452) 1452
adenine - therapeutic use (1446) 1446
tenofovir disoproxil fumarate (1438) 1438
pharmacology & pharmacy (1436) 1436
drug therapy (1329) 1329
lamivudine (1249) 1249
organophosphonates - therapeutic use (1231) 1231
antiretroviral therapy (1216) 1216
virology (1210) 1210
antiviral agents (1199) 1199
hiv infection (1131) 1131
anti-hiv agents - administration & dosage (1079) 1079
treatment outcome (1063) 1063
antiretroviral drugs (1026) 1026
health aspects (1013) 1013
aids/hiv (1010) 1010
research (984) 984
infection (968) 968
antiviral agents - therapeutic use (907) 907
anti-hiv agents - adverse effects (893) 893
therapy (890) 890
prevention (883) 883
adenine - administration & dosage (877) 877
hiv infections - prevention & control (846) 846
hepatitis b, chronic - drug therapy (845) 845
drug therapy, combination (842) 842
microbiology (818) 818
care and treatment (801) 801
viral load (783) 783
organophosphonates - administration & dosage (776) 776
gastroenterology & hepatology (772) 772
risk factors (760) 760
hepatitis b virus (736) 736
adenine - adverse effects (726) 726
deoxycytidine - analogs & derivatives (718) 718
hiv infections - virology (717) 717
hiv-1 - drug effects (666) 666
analysis (651) 651
aids (644) 644
safety (643) 643
entecavir (636) 636
highly active antiretroviral therapy (631) 631
young adult (630) 630
dosage and administration (628) 628
virus diseases (625) 625
organophosphonates - adverse effects (623) 623
hepatitis (620) 620
clinical trials (603) 603
pharmacokinetics (555) 555
hiv infections - complications (553) 553
disoproxil fumarate (552) 552
efavirenz (543) 543
lamivudine - therapeutic use (543) 543
reverse transcriptase inhibitors - therapeutic use (540) 540
tenofovir - therapeutic use (532) 532
animals (519) 519
human-immunodeficiency-virus (518) 518
medical research (513) 513
infections (504) 504
drug resistance (502) 502
acquired immune deficiency syndrome--aids (495) 495
drug resistance, viral (490) 490
efficacy (490) 490
patients (482) 482
adolescent (478) 478
drug combinations (475) 475
hiv-1 (469) 469
article (451) 451
double-blind (446) 446
aged (444) 444
human immunodeficiency virus (443) 443
mutation (441) 441
cd4 lymphocyte count (434) 434
abridged index medicus (432) 432
adenine - pharmacology (429) 429
retrospective studies (416) 416
adefovir dipivoxil (413) 413
pregnancy (412) 412
risk (409) 409
anti-hiv agents - pharmacology (406) 406
drugs (400) 400
medicine (399) 399
medicine, experimental (399) 399
deoxycytidine - therapeutic use (398) 398
antiretroviral agents (396) 396
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8590) 8590
Korean (133) 133
Spanish (123) 123
French (81) 81
German (71) 71
Chinese (23) 23
Hungarian (20) 20
Japanese (9) 9
Turkish (8) 8
Italian (7) 7
Czech (5) 5
Dutch (3) 3
Polish (3) 3
Portuguese (3) 3
Russian (2) 2
Croatian (1) 1
Hebrew (1) 1
Indonesian (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Etude observationnelle de l'evolution sur trois ans de la densite osseuse de 215 patients vivant avec le VIH, traites, avec ou sans Tenofovir, a distance de l'induction therapeutique
by Lansalot-Matras, Pauline and Delpierre, Cyrille and Massip, Patrice and Obadia, Martine and Bonnet, Eric and Sire, Stephane and Garipuy, Daniel and Aquilina, Christian and Cuzin, Lise and Marion-Latard, Fabrice and Bernard, Jacques
Revue du rhumatisme, ISSN 1169-8330, 05/2018, Volume 85, Issue 3, p. 270
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1016/j.rhum.2017.02.003 Comparer... 
Tenofovir
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Atteintes renales chez les personnes vivant avec le VIH traitees en Afrique par une combinaison antiretrovirale comprenant du tenofovir disoproxil fumarate
by Letertre-Gibert, P and Diallo, I and Pereira, B and Coban, D and Heng, A and Lesens, O and Laurichesse, H and Drabo, Y and Jacomet, C
Medecine et Maladies Infectieuses, ISSN 0399-077X, 06/2017, Volume 47, Issue 4, p. S137
Le tenofovir disoproxil fumarate (TDF) medicament antiretroviral est connu comme inducteur de nephrotoxicite comprenant tubulupathie proximale, insuffisance... 
Tenofovir
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text VIH-19 - Comparaison randomisee, en double aveugle, de tenofovir alafenamide , en association avec elvitegravir, cobicistat et emtricitabine en initiation de traitement du VIH-1 : resultats a 96 semaines
by Reynes, J and Yazdanpanah, Y and Cotte, L and Molina, J.-M and Ajana, F and Girard, P.-M and Katlama, C and Wohl, D and Das, M and Fordyce, M
Medecine et Maladies Infectieuses, ISSN 0399-077X, 06/2016, Volume 46, Issue 4, p. 123
Tenofovir
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text VIH-15 - Tenofovir alafenamide en remplacement de tenofovir disoproxil fumarate chez des adultes en succes virologique
by Raffi, F and Slama, L and Yazdanpanah, Y and Cheret, A and Reynes, J and Mingjin, Y and Cheng, A and Rhee, M
Medecine et Maladies Infectieuses, ISSN 0399-077X, 06/2016, Volume 46, Issue 4, p. 122
Tenofovir
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Tenofovir nephrotoxicity
by Isnard-Bagnis, Corinne and Aloy, Blandine and Deray, Gilbert and Tourret, JeRoMe
Nephrologie & Therapeutique, ISSN 1769-7255, 06/2016, Volume 12, Issue 3, p. 179
Le tenofovir est le seul inhibiteur nucleotidique de la transcriptase inverse du virus de l'immunodeficience humaine (VIH) actuellement commercialise. Bien... 
Tenofovir
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text High resistance barrier to tenofovir alafenamide is driven by higher loading of tenofovir diphosphate into target cells compared to tenofovir disoproxil fumarate
by Margot, Nicolas A and Liu, Yang and Miller, Michael D and Callebaut, Christian
Antiviral Research, ISSN 0166-3542, 08/2016, Volume 132, pp. 50 - 58
Tenofovir alafenamide (TAF) is a new oral prodrug of tenofovir (TFV) recently approved for the treatment of HIV-1 as part of the single-tablet regimen... 
Resistance | HIV-1 | Tenofovir alafenamide | Tenofovir diphosphate | Tenofovir disoproxil fumarate | ANTIRETROVIRAL-EXPERIENCED PATIENTS | VIROLOGICALLY SUPPRESSED ADULTS | ELVITEGRAVIR | HUMAN-IMMUNODEFICIENCY-VIRUS | NON-INFERIORITY | IN-VITRO | VIROLOGY | PRODRUG | DOUBLE-BLIND | ANTIVIRAL ACTIVITY | PHARMACOLOGY & PHARMACY | HIV-1 INFECTION | Anti-HIV Agents - pharmacology | Cell Line | HIV-1 - drug effects | HIV Infections - virology | Humans | Tenofovir - pharmacology | Drug Resistance, Viral | Reverse Transcriptase Inhibitors - pharmacology | Tenofovir - chemistry | HIV-1 - genetics | Reverse Transcriptase Inhibitors - chemistry | Viral Load | Dose-Response Relationship, Drug | Microbial Sensitivity Tests | Anti-HIV Agents - chemistry | Recombination, Genetic | Tenofovir - analogs & derivatives | RNA, Viral | Mutation | Tenofovir | Comparative analysis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Plasma tenofovir levels to support adherence to TDF/FTC preexposure prophylaxis for HIV prevention in MSM in Los Angeles, California
by Landovitz, Raphael J and Beymer, Matthew and Kofron, Ryan and Amico, Kathy Rivet and Psaros, Christina and Bushman, Lane and Anderson, Peter L and Flynn, Risa and Lee, David P and Bolan, Robert K and Jordan, Wilbert C and Tseng, Chi-Hong and Dierst-Davies, Rhodri and Rooney, Jim and Wohl, Amy Rock
Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 2017, Volume 76, Issue 5, pp. 501 - 511
Background: Tenofovir disoproxil fumarate/emtricitabine preexposure prophylaxis (PrEP) is effective against HIV acquisition when taken as prescribed.... 
Adherence | HIV prevention | PrEP | MSM | Preexposure prophylaxis | UNITED-STATES | INFECTIOUS DISEASES | COST-EFFECTIVENESS | SERVICES | adherence | SEX | EMTRICITABINE | IMMUNOLOGY | TRANSGENDER WOMEN | TRIAL | IMPACT | SEXUALLY-TRANSMITTED INFECTIONS | preexposure prophylaxis | MEN | HIV Infections - prevention & control | Tenofovir - blood | HIV Infections - epidemiology | Humans | Tenofovir - pharmacology | Los Angeles - epidemiology | Male | Tenofovir - administration & dosage | Pre-Exposure Prophylaxis | Young Adult | Transgender Persons | Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination - administration & dosage | Adolescent | Biomarkers | Adult | Female | Patient Compliance | Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination - pharmacology | Intervention | Emtricitabine | Drugs | Homosexuality | Identification methods | Prophylaxis | Sex | Health risks | Preventive medicine | Quantitation | Patient compliance | Adhesion | Seroconversion | Prevention | Tenofovir | Prescription drugs | Sexually transmitted diseases | Men | Bioindicators | Transgender persons | Index Medicus | AIDS/HIV
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Development and validation of an LC–MS/MS assay for tenofovir and tenofovir alafenamide in human plasma and cerebrospinal fluid
by Ocque, Andrew J and Hagler, Colleen E and Morse, Gene D and Letendre, Scott L and Ma, Qing
Journal of Pharmaceutical and Biomedical Analysis, ISSN 0731-7085, 07/2018, Volume 156, pp. 163 - 169
A liquid chromatography with triple quadrupole mass spectrometry method was developed and validated for the determination of tenofovir and tenofovir... 
Tenofovir | Plasma | Cerebrospinal fluid | Tenofovir alafenamide | Mass spectrometry | CHEMISTRY, ANALYTICAL | LABELED INTERNAL STANDARDS | ELVITEGRAVIR | EMTRICITABINE | IMPLEMENTATION | HUMAN-IMMUNODEFICIENCY-VIRUS | TANDEM MASS-SPECTROMETRY | REVERSE-TRANSCRIPTASE INHIBITOR | PHARMACOKINETICS | PRODRUG | PHARMACOLOGY & PHARMACY | SIMULTANEOUS QUANTIFICATION | Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination - analysis | HIV Infections - blood | HIV Infections - cerebrospinal fluid | Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination - therapeutic use | Emtricitabine - therapeutic use | Reproducibility of Results | Adenine - analogs & derivatives | Tenofovir - therapeutic use | Humans | Adenine - analysis | Chromatography, High Pressure Liquid | Anti-HIV Agents - analysis | Tandem Mass Spectrometry | Adenine - therapeutic use | Emtricitabine - analysis | Tenofovir - analogs & derivatives | Quinolones - analysis | Quinolones - therapeutic use | Solid Phase Extraction | Tenofovir - analysis | Cobicistat - analysis | HIV Infections - drug therapy | Cobicistat - therapeutic use | Drug Combinations | Antiviral agents | Ionization | Analysis | Pharmacy | Formic acid | Nitriles | Liquid chromatography | Organic acids | Index Medicus | mass spectrometry | tenofovir alafenamide | plasma | tenofovir | cerebrospinal fluid
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment–Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide
by Margot, Nicolas A and Wong, Pamela and Kulkarni, Rima and White, Kirsten and Porter, Danielle and Abram, Michael E and Callebaut, Christian and Miller, Michael D
The Journal of Infectious Diseases, ISSN 0022-1899, 03/2017, Volume 215, Issue 6, pp. 920 - 927
Abstract Background. The presence of transmitted drug resistance mutations (TDRMs) in antiretroviral treatment (ART)–naive patients can adversely affect the... 
HIV-1 | Transmitted resistance | Tenofovir alafenamide | Tenofovir disoproxil fumarate | WILD-TYPE | INFECTIOUS DISEASES | EMTRICITABINE | CO-FORMULATED ELVITEGRAVIR | INITIAL TREATMENT | MICROBIOLOGY | transmitted resistance | tenofovir disoproxil fumarate | IMMUNOLOGY | CLINICAL MANAGEMENT | EFAVIRENZ/EMTRICITABINE/TENOFOVIR DF | IMMUNODEFICIENCY-VIRUS TYPE-1 | DOUBLE-BLIND | tenofovir alafenamide | INFECTION | ELVITEGRAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR DF | Emtricitabine - therapeutic use | Adenine - analogs & derivatives | Tenofovir - therapeutic use | HIV-1 - drug effects | United States | Europe | Humans | Male | Mutation, Missense | HIV-1 - genetics | Drug Resistance, Viral - genetics | Thymidine - analogs & derivatives | Adenine - therapeutic use | Lamivudine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | HIV Infections - drug therapy | Reverse Transcriptase Inhibitors - therapeutic use | Tenofovir | Dosage and administration | Research | RNA | Drug resistance | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women
by Klatt, Nichole R and Cheu, Ryan and Birse, Kenzie and Zevin, Alexander S and Perner, Michelle and Noël-Romas, Laura and Grobler, Anneke and Westmacott, Garrett and Xie, Irene Y and Butler, Jennifer and Mansoor, Leila and McKinnon, Lyle R and Passmore, Jo-Ann S and Karim, Quarraisha Abdool and Karim, Salim S. Abdool and Burgener, Adam D
Science, ISSN 0036-8075, 06/2017, Volume 356, Issue 6341, pp. 938 - 945
Antiretroviral-based strategies for HIV prevention have shown inconsistent results in women. We investigated whether vaginal microbiota modulated tenofovir gel... 
TRANSMISSION | PHARMACOLOGY | MULTIDISCIPLINARY SCIENCES | ACQUISITION | VAGINOSIS | RISK | INFECTION | LACTOBACILLI | PREEXPOSURE PROPHYLAXIS | IDENTIFICATION | GENITAL-TRACT | HIV Infections - prevention & control | Antiviral Agents - pharmacology | Bacteria - metabolism | Microbiota - physiology | Humans | Tenofovir - pharmacology | Proteome | Antiviral Agents - metabolism | Biodiversity | Lactobacillus - metabolism | Bacteria - genetics | HIV Infections - microbiology | Bacteria - isolation & purification | Microbiota - genetics | Mass Spectrometry | Tenofovir - analysis | Tenofovir - metabolism | RNA, Ribosomal, 16S - genetics | Adult | Female | South Africa | Vagina - microbiology | Gardnerella - metabolism | Anaerobic bacteria | Medical research | Correlation | Effectiveness | Communities | Mucosa | Clinical trials | Vagina | Pharmacology | Infections | Metabolism | Incidence | Prevention | Tenofovir | Depletion | Acquired immune deficiency syndrome--AIDS | Antiretroviral agents | Human immunodeficiency virus--HIV | Men | Bacteria | Index Medicus | Drugs | Strategy | Human immunodeficiency virus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Stability behaviour of antiretroviral drugs and their combinations. 4: Characterization of degradation products of tenofovir alafenamide fumarate and comparison of its degradation and stability behaviour with tenofovir disoproxil fumarate
by Golla, Vijaya Madhyanapu and Kurmi, Moolchand and Shaik, Karimullah and Singh, Saranjit
Journal of Pharmaceutical and Biomedical Analysis, ISSN 0731-7085, 11/2016, Volume 131, pp. 146 - 155
In this study, stress degradation behaviour of tenofovir alafenamide fumarate (TAF), a novel prodrug of tenofovir, was investigated and compared with currently... 
MSn | Tenofovir alafenamide fumarate | Prodrug | LC-HRMS | Tenofovir disoproxil fumarate | MS | CHEMISTRY, ANALYTICAL | IN-VITRO | PHARMACOLOGY & PHARMACY | HUMAN-IMMUNODEFICIENCY-VIRUS | Anti-Retroviral Agents - chemistry | Prodrugs - analysis | Drug Stability | Humans | Tenofovir - chemistry | Prodrugs - chemistry | Prodrugs - metabolism | Anti-Retroviral Agents - metabolism | Anti-HIV Agents - analysis | Anti-HIV Agents - chemistry | Anti-Retroviral Agents - analysis | Tenofovir - analysis | Tenofovir - metabolism | Anti-HIV Agents - metabolism | Tenofovir | Comparative analysis | Highly active antiretroviral therapy | Drugs | Mass spectrometry | High performance liquid chromatography | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Acquired Fanconi's Syndrome Associated with Tenofovir Therapy
by Mathew, George and Knaus, Stephen J
Journal of General Internal Medicine, ISSN 0884-8734, 11/2006, Volume 21, Issue 11, p. 1206
Tenofovir
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Pharmacokinetic and Tissue Distribution Profile of Long Acting Tenofovir Alafenamide and Elvitegravir Loaded Nanoparticles in Humanized Mice Model
by Prathipati, Pavan Kumar and Mandal, Subhra and Pon, Gregory and Vivekanandan, Renuga and Destache, Christopher J
Pharmaceutical Research, ISSN 0724-8741, 12/2017, Volume 34, Issue 12, pp. 2749 - 2755
Non-adherence to the antiretroviral (ARV) regimen is a critical factor in determining efficacy of ARV drugs for pre-exposure prophylaxis (PrEP). A long-acting... 
Biochemistry, general | tissue distribution profile | nanoformulation | Biomedicine | Pharmacy | elvitegravir | pharmacokinetics | Medical Law | tenofovir alafenamide | Pharmacology/Toxicology | Biomedical Engineering and Bioengineering | WOMEN | TRANSMISSION | HIV PREEXPOSURE PROPHYLAXIS | PREVENTION | PHARMACOLOGY & PHARMACY | DOLUTEGRAVIR | CHEMISTRY, MULTIDISCIPLINARY | Tenofovir - blood | Nanoparticles - chemistry | Humans | Tenofovir - chemistry | Delayed-Action Preparations - chemistry | Tenofovir - administration & dosage | Tenofovir - pharmacokinetics | Drug Carriers - chemistry | Anti-HIV Agents - administration & dosage | Tissue Distribution | Quinolones - blood | Anti-HIV Agents - chemistry | Quinolones - administration & dosage | Animals | Quinolones - chemistry | Quinolones - pharmacokinetics | Anti-HIV Agents - pharmacokinetics | Female | HIV Infections - drug therapy | Mice | Anti-HIV Agents - blood | Tenofovir | Medical colleges | Analysis | CD34 antigen | Drugs | Stress concentration | Dosing | Prophylaxis | Radioactive half-life | Pharmacology | Exposure | Nanoparticles | Load distribution (forces) | Antiretroviral agents | Rodents | Sustained release | Drug dosages | Controlled release | Index Medicus | Pharmacokinetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text The Epi-TAF for tenofovir disoproxil fumarate?
by Walensky, Rochelle P and Horn, Tim H and Paltiel, A. David
Clinical Infectious Diseases, ISSN 1058-4838, 04/2016, Volume 62, Issue 7, pp. 915 - 918
Approximately 84% of human immunodeficiency virus (HIV)-infected US residents on antiretroviral therapy currently receive some form of tenofovir disoproxil... 
cost-effectiveness | costs | tenofovir alafenamide | tenofovir disoproxil fumarate | generics | Bone Diseases - chemically induced | Anti-HIV Agents - economics | Tenofovir - adverse effects | Tenofovir - therapeutic use | HIV Infections - economics | United States | Anti-HIV Agents - adverse effects | Humans | Tenofovir - economics | Cost-Benefit Analysis | Kidney Diseases - chemically induced | Anti-HIV Agents - therapeutic use | HIV Infections - drug therapy | Tenofovir | Diagnosis | Research | HIV (Viruses) | Antiretroviral drugs | Toxicity | Human immunodeficiency virus--HIV | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text An intravaginal ring for the sustained delivery of tenofovir disoproxil fumarate
by Baum, Marc M and Butkyavichene, Irina and Churchman, Scott A and Lopez, Gilbert and Miller, Christine S and Smith, Thomas J and Moss, John A
International Journal of Pharmaceutics, ISSN 0378-5173, 11/2015, Volume 495, Issue 1, pp. 579 - 587
Recent clinical trials have demonstrated that pre-exposure prophylaxis (PrEP) may prevent HIV infection in a significant number of HIV-1 negative individuals... 
HIV/AIDS | Tenofovir | Antiretroviral | Sustained release | Pre-exposure prophylaxis | Intravaginal ring | Tenofovir disoproxil (PubChem CID: 5481350) | Tenofovir (PubChem CID: 464205) | Tenofovir monoisoproxil (PubChem CID: 56925685) | Chemical compounds studied in this article Tenofovir disoproxil fumarate (PubChem CID: 6398764) | MEDICATION | HIV PREVENTION | VAGINAL FLUID | MICROBICIDES | ADHERENCE | WOMEN | IN-VITRO | PHARMACOKINETICS | ANTIRETROVIRAL PREEXPOSURE PROPHYLAXIS | PHARMACOLOGY & PHARMACY | INFECTION | Anti-HIV Agents - administration & dosage | HIV Infections - prevention & control | Pre-Exposure Prophylaxis - methods | Humans | Drug Liberation | Administration, Intravaginal | Tenofovir - administration & dosage | Delayed-Action Preparations | Prevention | Medicine, Experimental | Medical research | HIV infection | Index Medicus | antiretroviral | HIV | sustained release | tenofovir | AIDS | intravaginal ring
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text The Lipid-Lowering Effect of Tenofovir/Emtricitabine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial
by Santos, José R and Saumoy, María and Curran, Adrian and Bravo, Isabel and Llibre, Josep M and Navarro, Jordi and Estany, Carla and Podzamczer, Daniel and Ribera, Esteban and Negredo, Eugènia and Clotet, Bonaventura and Paredes, Roger and Tenofovir Emtricitabine InflUence and Tenofovir/emtricitabine inflUence on LIPid metabolism (TULIP) Study Group
Clinical Infectious Diseases, ISSN 1058-4838, 08/2015, Volume 61, Issue 3, pp. 403 - 408
Background. It is unknown if tenofovir disoproxil fumarate (TDF), which is often coformulated with the lipidneutral emtricitabine (FTC), has a lipid-lowering... 
boosted protease inhibitor monotherapy | LDL cholesterol | coformulated tenofovir/emtricitabine | total cholesterol | lipid-lowering effect | INFECTIOUS DISEASES | PROFILES | ANTIRETROVIRAL-NAIVE PATIENTS | EMTRICITABINE | ZIDOVUDINE/LAMIVUDINE | MICROBIOLOGY | TOXICITY | DARUNAVIR/RITONAVIR | IMMUNOLOGY | TENOFOVIR DISOPROXIL FUMARATE | HIV-INFECTION | THERAPY | EFAVIRENZ | Anti-HIV Agents - pharmacology | Emtricitabine - therapeutic use | Double-Blind Method | Tenofovir - therapeutic use | HIV Infections - epidemiology | Humans | Middle Aged | Tenofovir - pharmacology | Male | Emtricitabine - pharmacology | Cross-Over Studies | Lipids - blood | Placebos | Adult | Anti-HIV Agents - therapeutic use | Female | HIV Infections - drug therapy | HIV Infections - physiopathology | Emtricitabine | Tenofovir | Treatment outcome | Usage | Analysis | Clinical trials | HIV patients | Lipids | Dosage and administration | Health aspects | Antiretroviral drugs | Triglycerides | Low density lipoprotein | Human immunodeficiency virus--HIV | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text A LC/MS/MS method for determination of tenofovir in human plasma and its application to toxicity monitoring
by Wiriyakosol, Narit and Puangpetch, Apichaya and Manosuthi, Weerawut and Tomongkon, Sasinapha and Sukasem, Chonlaphat and Pinthong, Darawan
Journal of Chromatography B, ISSN 1570-0232, 05/2018, Volume 1085, pp. 89 - 95
Tenofovir disoproxil fumarate is a pro-drug of the active metabolite tenofovir widely used against the HIV1, HIV2, and Hepatitis B virus. Several studies have... 
Tenofovir | HIV-1 | LC/MS/MS | Kidney injury | Tenofovir plasma concentration | CHEMISTRY, ANALYTICAL | ASSAY | EMTRICITABINE | BIOCHEMICAL RESEARCH METHODS | MS METHOD | HIV-INFECTED PATIENTS | REVERSE-TRANSCRIPTASE INHIBITOR | GLOMERULAR-FILTRATION-RATE | LAMIVUDINE | DISOPROXIL FUMARATE | DYSFUNCTION | Tenofovir - blood | Reproducibility of Results | Tenofovir - adverse effects | Tenofovir - therapeutic use | Anti-HIV Agents - adverse effects | Humans | Linear Models | Tenofovir - pharmacokinetics | Anti-HIV Agents - pharmacokinetics | Sensitivity and Specificity | Anti-HIV Agents - therapeutic use | HIV Infections - drug therapy | Anti-HIV Agents - blood | Chromatography, Liquid - methods | Drug Monitoring | Tandem Mass Spectrometry - methods | Medical research | Antiviral agents | Pharmacogenetics | Metabolites | Ionization | Formic acid | Medicine, Experimental | Nitriles | Methods | Organic acids | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
18. Full Text Impact of sex on the pharmacokinetics and pharmacodynamics of 1% tenofovir gel
by Herold, Betsy C and Chen, Beatrice A and Salata, Robert A and Marzinke, Mark A and Kelly, Clifton W and Dezzutti, Charlene S and Mcgowan, Ian and Galaska, Beth and Levy, Lisa and Piper, Jeanna M and Hillier, Sharon and Hendrix, Craig W and MTN-011 Study Team
Clinical Infectious Diseases, ISSN 1058-4838, 02/2016, Volume 62, Issue 3, pp. 375 - 382
Background. Tenofovir (TFV) gel partially protected against human immunodeficiency virus (HIV) in one but not subsequent trials. The disappointing results were... 
pharmacokinetics | tenofovir gel | HIV | MTN-011 | post-coital | INFECTIOUS DISEASES | SEMINAL PLASMA | MICROBICIDE | SIMPLEX-VIRUS INFECTION | MICROBIOLOGY | IMMUNOLOGY | HIV-INFECTION | ANTIRETROVIRAL PROPHYLAXIS | DISOPROXIL FUMARATE | DOUBLE-BLIND | INTRAVAGINAL RING | ANTIVIRAL ACTIVITY | PREEXPOSURE PROPHYLAXIS | Anti-HIV Agents - pharmacology | HIV Infections - prevention & control | Pre-Exposure Prophylaxis - methods | Gels - administration & dosage | Humans | Tenofovir - pharmacology | Male | Tenofovir - administration & dosage | Tenofovir - pharmacokinetics | HIV - drug effects | Anti-HIV Agents - administration & dosage | Microbial Sensitivity Tests | Young Adult | Anti-HIV Agents - analysis | Tandem Mass Spectrometry | Time Factors | Vaginal Douching | Anti-HIV Agents - pharmacokinetics | Adolescent | Sex Factors | Tenofovir - analysis | Chromatography, Liquid | Adult | Female | Tenofovir | Care and treatment | Dosage and administration | Pharmacokinetics | HIV infection | Analysis | Clinical trials | Antiretroviral drugs | Pharmacology | Human immunodeficiency virus--HIV | Clinical outcomes | Sexual behavior | Index Medicus | AIDS
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights